Clinical trials: Neuroendocrine Carcinomas
- Condition Neuroendocrine Carcinomas
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Carcinoid Syndrome
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c.
- Trial name
- ELECT (NCT00774930)
- Testing
- Lanreotide
- Where
- 54 sites in United States, Brazil and 9 more
- Volunteers
- 115 people
- Sponsor
- Ipsen
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Malignant Melanoma, Squamous Cell Carcinoma of Skin
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with…
- Trial name
- NCT04913220
- Testing
- THOR-707, Cemiplimab
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 46 people
- Sponsor
- Sanofi
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Metastatic Melanoma, Head Neck Cancer
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in…
- Trial name
- NCT02521870
- Testing
- SD-101(1), Pembrolizumab, SD-101(2)
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 241 people
- Sponsor
- Dynavax Technologies Corporation
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma, Melanoma
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b…
- Trial name
- NCT02089685
- Testing
- Pembrolizumab, PegIFN-2b, Ipilimumab
- Volunteers
- 295 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Neoplasms, Neoplasm Metastasis
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
- Conditions
- Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT02014116
- Testing
- LY3009120 capsule
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company